Brief: Kairos Pharma Announces Positive Safety Results From Phase 2 Trial Of ENV-105 In Advanced Prostate Cancer
15/07/2025 13:22
July 15 (Reuters) - Kairos Pharma Ltd KAPA.A: KAIROS PHARMA ANNOUNCES POSITIVE SAFETY RESULTS FROM PHASE 2 TRIAL OF ENV-105 IN ADVANCED PROSTATE CANCER KAIROS PHARMA LTD - ENV-105 WELL TOLERATED WITH HORMONE THERAPY IN PHASE 2 TRIAL KAIROS PHARMA LTD - NO DOSE-LIMITING TOXICITIES OR UNEXPECTED ADVERSE EVENTS REPORTED KAIROS PHARMA LTD - INTERIM EFFICACY DATA EXPECTED IN SEPTEMBER 2025 Source text: ID:nBw3wNY0ga Further company coverage: KAPA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kairos Pharma
See all newsBrief: Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics
Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer